Probably unrealistic to expect rapid conversion to BCT technology at large pharmas. Design, building, and implementation of sample handling systems takes years and incorporates complex procedures, employee training, enterprise software integration, etc. Establishing beachheads is positive news but expansion from there is challenging unless there is a compelling technical reason for making changes. Also, not sure if BCT alone could meet vendor qualification requirements with respect to strength of balance sheet, stock levels, etc. Perhaps an alliance with a well established company would speed penetration?
- Forums
- ASX - By Stock
- Ann: Open Briefing
Probably unrealistic to expect rapid conversion to BCT...
Featured News
Add BCT (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.616M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
BCT (ASX) Chart |
Day chart unavailable